gilead-sciences

Gilead buys Novartis’ herpes, flu and cold virus preclinical programmes

pharmafile | July 23, 2019 | News story | Manufacturing and Production |  Gilead, Novartis, antivrial, deal, herpes, influenza, rhinovirus 

Gilead has acquired the rights to three of Novartis’ preclinical antiviral programmes, including investigational compounds with the potential to treat influenza, herpes and human rhinovirus, the virus that causes the common cold.

The deal will see Gilead acquire the exclusive global rights to develop and commercialise novel small molecules against the three undisclosed targets.

The deal will see Novartis receive an upfront payment of an undisclosed amount and up to $291 million in milestone payments on reaching commercial and developmental milestones.

Advertisement

“Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said Dr John McHutchison, Gilead’s Chief Scientific Officer and Head of Research and Development.  

The deal will see Gilead build on its core competency of virology and infectious diseases. The Foster City-firm’s antiviral portfolio includes some of the most widely sued medicines for Hepatitis B (HBV), Hepatitis C (HCV) and HIV. The deal represents Gilead’s move into mass market therapeutic areas. 

Louis Goss

Related Content

Gilead’s HIV treatment meets primary trial endpoint

Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a …

Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia

Gilead has announced the first shipments of its HIV prevention drug lenacapavir to Eswatini and …

Novartis receives SMC approval for early breast cancer treatment

Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

The Gateway to Local Adoption Series

Latest content